Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis Opinion EDITORIAL Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis Daniel M. Hartung, PharmD, MPH; Dennis Bourdette, MD In 1993, the first disease modifying-therapy (DMT) for mul- nually. The authors also note the disturbing trends that DMT costs increased in parallel and the entry of new products seems tiple sclerosis (MS), interferon beta-1b, was approved, and an untreatable disease that had disabled humans for hundreds to only propel costs higher, phenomena previously noted and of years became treatable. Since then, multiple drugs with also apparent in the Figure. As a consequence of escalating varying mechanisms of ac- costs and Part D benefit design, the out-of-pocket expenses to tion have been approved, and patients during this same time rose 7-fold, from $372 to $2673 Related article page 1386 neurologists now have a pal- per 1000 beneficiaries. ette of therapies that allows for individualizing therapy and This study by San-Juan-Rodriguez and colleagues is an im- effectively controlling relapsing MS in most patients. Regret- portant addition to the literature on the rising cost of DMTs tably, this achievement has come at a steep price. Interferon for MS. Their study documents the escalating costs that beta-1b entered the market with an http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Neurology American Medical Association

Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis

Hartung, Daniel M.; Bourdette, Dennis
JAMA Neurology , Volume 76 (11) – Nov 26, 2019
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/addressing-the-rising-prices-of-disease-modifying-therapies-for-QuuFBntv8i

References (13)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6149
eISSN
2168-6157
DOI
10.1001/jamaneurol.2019.2445
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Addressing the Rising Prices of Disease-Modifying Therapies for Multiple Sclerosis Daniel M. Hartung, PharmD, MPH; Dennis Bourdette, MD In 1993, the first disease modifying-therapy (DMT) for mul- nually. The authors also note the disturbing trends that DMT costs increased in parallel and the entry of new products seems tiple sclerosis (MS), interferon beta-1b, was approved, and an untreatable disease that had disabled humans for hundreds to only propel costs higher, phenomena previously noted and of years became treatable. Since then, multiple drugs with also apparent in the Figure. As a consequence of escalating varying mechanisms of ac- costs and Part D benefit design, the out-of-pocket expenses to tion have been approved, and patients during this same time rose 7-fold, from $372 to $2673 Related article page 1386 neurologists now have a pal- per 1000 beneficiaries. ette of therapies that allows for individualizing therapy and This study by San-Juan-Rodriguez and colleagues is an im- effectively controlling relapsing MS in most patients. Regret- portant addition to the literature on the rising cost of DMTs tably, this achievement has come at a steep price. Interferon for MS. Their study documents the escalating costs that beta-1b entered the market with an

Journal

JAMA Neurology – American Medical Association

Published: Nov 26, 2019

There are no references for this article.